MedTrace Logo

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

NCT00563446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-06-16

No results posted yet for this study

Summary

Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rHuEPO). Darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rHuEPO, which allows dosing at extended intervals and less frequent injection.

The objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.

Conditions

  • Anemia
  • Kidney Failure, Chronic
  • Peritoneal Dialysis, Continuous Ambulatory

Interventions

DRUG

Darbepoetin alfa

Sponsors & Collaborators

  • Kirin Pharmaceutical (Asia) CO., LTD

    collaborator UNKNOWN

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Principal Investigators

  • Samuel KS Fung, Dr · Division of Nephrology, Medicine & Geriatrics, Princess Margaret Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2006-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563446 on ClinicalTrials.gov